Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Overview

USA - NASDAQ:LXEO - US52886X1072 - Common Stock

9.22 USD
-0.36 (-3.76%)
Last: 10/20/2025, 5:41:26 PM
9.5 USD
+0.28 (+3.04%)
After Hours: 10/20/2025, 5:41:26 PM

LXEO Key Statistics, Chart & Performance

Key Statistics
Market Cap497.88M
Revenue(TTM)N/A
Net Income(TTM)-114172000
Shares54.00M
Float49.10M
52 Week High11.72
52 Week Low1.45
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.26
PEN/A
Fwd PEN/A
Earnings (Next)11-13 2025-11-13/bmo
IPO2023-11-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


LXEO short term performance overview.The bars show the price performance of LXEO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

LXEO long term performance overview.The bars show the price performance of LXEO in the last 1, 2 and 3 years. 1 year 2 years 3 years -0.5 -1 -1.5 -2 -2.5

The current stock price of LXEO is 9.22 USD. In the past month the price increased by 73.63%. In the past year, price decreased by -2.95%.

LEXEO THERAPEUTICS INC / LXEO Daily stock chart

LXEO Latest News, Press Relases and Analysis

LXEO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.91 409.95B
AMGN AMGEN INC 13.91 163.30B
GILD GILEAD SCIENCES INC 15.91 152.76B
VRTX VERTEX PHARMACEUTICALS INC 24.74 107.45B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 64.39B
REGN REGENERON PHARMACEUTICALS 12.64 61.13B
ARGX ARGENX SE - ADR 92.23 52.30B
INSM INSMED INC N/A 35.49B
ONC BEONE MEDICINES LTD-ADR 5.15 34.99B
BNTX BIONTECH SE-ADR N/A 25.95B
NTRA NATERA INC N/A 25.89B
BIIB BIOGEN INC 9.16 21.50B

About LXEO

Company Profile

LXEO logo image Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Company Info

LEXEO THERAPEUTICS INC

345 Park Avenue South, Floor 6

New York City NEW YORK US

Employees: 72

LXEO Company Website

Phone: 12125479879

LEXEO THERAPEUTICS INC / LXEO FAQ

What is the stock price of LEXEO THERAPEUTICS INC today?

The current stock price of LXEO is 9.22 USD. The price decreased by -3.76% in the last trading session.


What is the ticker symbol for LEXEO THERAPEUTICS INC stock?

The exchange symbol of LEXEO THERAPEUTICS INC is LXEO and it is listed on the Nasdaq exchange.


On which exchange is LXEO stock listed?

LXEO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LEXEO THERAPEUTICS INC stock?

14 analysts have analysed LXEO and the average price target is 17.78 USD. This implies a price increase of 92.81% is expected in the next year compared to the current price of 9.22. Check the LEXEO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LEXEO THERAPEUTICS INC worth?

LEXEO THERAPEUTICS INC (LXEO) has a market capitalization of 497.88M USD. This makes LXEO a Small Cap stock.


How many employees does LEXEO THERAPEUTICS INC have?

LEXEO THERAPEUTICS INC (LXEO) currently has 72 employees.


What are the support and resistance levels for LEXEO THERAPEUTICS INC (LXEO) stock?

LEXEO THERAPEUTICS INC (LXEO) has a support level at 7.67 and a resistance level at 9.59. Check the full technical report for a detailed analysis of LXEO support and resistance levels.


Should I buy LEXEO THERAPEUTICS INC (LXEO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LEXEO THERAPEUTICS INC (LXEO) stock pay dividends?

LXEO does not pay a dividend.


When does LEXEO THERAPEUTICS INC (LXEO) report earnings?

LEXEO THERAPEUTICS INC (LXEO) will report earnings on 2025-11-13, before the market open.


What is the Price/Earnings (PE) ratio of LEXEO THERAPEUTICS INC (LXEO)?

LEXEO THERAPEUTICS INC (LXEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.26).


What is the Short Interest ratio of LEXEO THERAPEUTICS INC (LXEO) stock?

The outstanding short interest for LEXEO THERAPEUTICS INC (LXEO) is 12% of its float. Check the ownership tab for more information on the LXEO short interest.


LXEO Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to LXEO. When comparing the yearly performance of all stocks, LXEO is one of the better performing stocks in the market, outperforming 93.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LXEO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LXEO. The financial health of LXEO is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LXEO Financial Highlights

Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -3.26. The EPS increased by 77.7% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -64.85%
ROE -82.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%6.25%
Sales Q2Q%N/A
EPS 1Y (TTM)77.7%
Revenue 1Y (TTM)N/A

LXEO Forecast & Estimates

14 analysts have analysed LXEO and the average price target is 17.78 USD. This implies a price increase of 92.81% is expected in the next year compared to the current price of 9.22.


Analysts
Analysts87.14
Price Target17.78 (92.84%)
EPS Next Y16.55%
Revenue Next YearN/A

LXEO Ownership

Ownership
Inst Owners80.84%
Ins Owners0.5%
Short Float %12%
Short Ratio10.87